LUPIN.NS
Lupin Limited [LUPIN.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LUPIN.NS Stock Summary
Top 10 Correlated ETFs
LUPIN.NS
Top 10 Correlated Stocks
LUPIN.NS
In the News
LUPIN.NS Financial details
Company Rating
Buy
Market Cap
739.24B
Income
17.91B
Revenue
190.92B
Book val./share
-
Cash/share
-
Dividend
4
Dividend %
0.28%
Employees
20.93K
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
47.95
Forward P/E
-
PEG
-2.21
P/S
3.51
P/B
4.82
P/C
-
P/FCF
1095.18
Quick Ratio
0.76
Current Ratio
1.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
39.36
EPS next Y
-
EPS next Q
-
EPS this Y
-128.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.74%
Revenue last 5Y
-0.12%
Revenue Q/Q
2.85%
EPS Q/Q
25.19%
-
-
-
-
SMA20
-2.67%
SMA50
7.86%
SMA100
34.53%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
21%
ROC
0.14%
Gross Margin
63%
Oper. Margin
11%
Profit Margin
7%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
655.4-1704.25
52W High
-6.45%
52W Low
+143.37%
RSI
48
Rel Volume
0.62
Avg Volume
1.2M
Volume
746.8K
Perf Week
-0.33%
Perf Month
-1.88%
Perf Quarter
36.48%
Perf Half Y
33.03%
-
-
-
-
Beta
0.65
-
-
Volatility
7.95%, 29.23%
Prev Close
-1.08%
Price
1594.05
Change
-0.74%
LUPIN.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 361.96 | 334.49 | 329.31 | 356.64 | 357.82 | |
| Net income per share | 13.41 | -5.95 | 26.84 | -33.65 | 9.46 | |
| Operating cash flow per share | 36.84 | 32.45 | 40.19 | 8.09 | 41.72 | |
| Free cash flow per share | 15.05 | 17.58 | 25.24 | -11.84 | 8.74 | |
| Cash per share | 69.22 | 107.99 | 92.53 | 46.34 | 50.34 | |
| Book value per share | 303.87 | 276.92 | 304.52 | 267.67 | 274.13 | |
| Tangible book value per share | 154.62 | 194.98 | 223.82 | 200.23 | 186.71 | |
| Share holders equity per share | 303.87 | 276.92 | 304.52 | 267.67 | 274.13 | |
| Interest debt per share | 193.79 | 153.85 | 115.75 | 93.95 | 105.91 | |
| Market cap | 346.51B | 266.94B | 462.55B | 339.19B | 294.82B | |
| Enterprise value | 421.67B | 308.73B | 496.49B | 369.88B | 327.92B | |
| P/E ratio | 57.13 | -99.09 | 38.02 | -22.2 | 68.55 | |
| Price to sales ratio | 2.12 | 1.76 | 3.1 | 2.09 | 1.81 | |
| POCF ratio | 20.8 | 18.17 | 25.39 | 92.35 | 15.54 | |
| PFCF ratio | 50.91 | 33.55 | 40.43 | -63.07 | 74.2 | |
| P/B Ratio | 2.52 | 2.13 | 3.35 | 2.79 | 2.37 | |
| PTB ratio | 2.52 | 2.13 | 3.35 | 2.79 | 2.37 | |
| EV to sales | 2.58 | 2.04 | 3.33 | 2.28 | 2.02 | |
| Enterprise value over EBITDA | 13.53 | 10.64 | 19.13 | 15.75 | 17.52 | |
| EV to operating cash flow | 25.31 | 21.02 | 27.25 | 100.7 | 17.29 | |
| EV to free cash flow | 61.95 | 38.8 | 43.39 | -68.78 | 82.52 | |
| Earnings yield | 0.02 | -0.01 | 0.03 | -0.05 | 0.01 | |
| Free cash flow yield | 0.02 | 0.03 | 0.02 | -0.02 | 0.01 | |
| Debt to equity | 0.62 | 0.53 | 0.37 | 0.34 | 0.36 | |
| Debt to assets | 0.3 | 0.27 | 0.22 | 0.19 | 0.2 | |
| Net debt to EBITDA | 2.41 | 1.44 | 1.31 | 1.31 | 1.77 | |
| Current ratio | 2.26 | 1.67 | 1.66 | 1.51 | 1.34 | |
| Interest coverage | 6.4 | 4.03 | 14.93 | 11.73 | 3.11 | |
| Income quality | 1.1 | 1.68 | 1.09 | -0.27 | 2.65 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.37 | -0.84 | 0.22 | -0.19 | 0.42 | |
| Sales general and administrative to revenue | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | |
| Research and developement to revenue | 0.09 | 0.1 | 0.1 | 0.09 | 0.08 | |
| Intangibles to total assets | 0.24 | 0.15 | 0.16 | 0.14 | 0.18 | |
| Capex to operating cash flow | -0.59 | -0.46 | -0.37 | -2.46 | -0.79 | |
| Capex to revenue | -0.06 | -0.04 | -0.05 | -0.06 | -0.09 | |
| Capex to depreciation | -0.91 | -0.58 | -0.76 | -0.55 | -1.7 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 302.82 | 192.55 | 428.82 | 450.2 | 241.54 | |
| ROIC | 0.03 | -0.04 | 0.07 | 0.08 | 0.03 | |
| Return on tangible assets | 0.03 | -0.01 | 0.06 | -0.08 | 0.02 | |
| Graham Net | -87.36 | -10.8 | 16.74 | -19.63 | -54.73 | |
| Working capital | 77.24B | 61.88B | 55.5B | 41.81B | 31.86B | |
| Tangible asset value | 69.93B | 88.27B | 101.46B | 90.91B | 84.89B | |
| Net current asset value | -3.07B | 30.11B | 42.34B | 28.58B | 20.38B | |
| Invested capital | 0.62 | 0.53 | 0.37 | 0.34 | 0.36 | |
| Average receivables | 68.57B | 69.71B | 63.78B | 57.06B | 51.19B | |
| Average payables | 25.37B | 24.55B | 22.13B | 21.49B | 24.07B | |
| Average inventory | 37.5B | 36.47B | 37.74B | 43.61B | 45.61B | |
| Days sales outstanding | 153.43 | 170.22 | 139.26 | 128.88 | 101.39 | |
| Days payables outstanding | 144.49 | 147.43 | 124.27 | 117.56 | 136.29 | |
| Days of inventory on hand | 221.91 | 211.27 | 252.44 | 238.46 | 241.82 | |
| Receivables turnover | 2.38 | 2.14 | 2.62 | 2.83 | 3.6 | |
| Payables turnover | 2.53 | 2.48 | 2.94 | 3.1 | 2.68 | |
| Inventory turnover | 1.64 | 1.73 | 1.45 | 1.53 | 1.51 | |
| ROE | 0.04 | -0.02 | 0.09 | -0.13 | 0.03 | |
| Capex per share | -21.79 | -14.87 | -14.95 | -19.93 | -32.98 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 93.34 | 95.18 | 104.22 | 108.53 | 111.57 | |
| Net income per share | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | |
| Operating cash flow per share | 9.69 | 1.28 | 10.31 | 10.89 | 11.3 | |
| Free cash flow per share | 9.69 | 1.28 | 10.31 | 10.89 | 11.3 | |
| Cash per share | 25.61 | 50.31 | 37.75 | 49.68 | 0 | |
| Book value per share | 262.2 | 273.96 | 275.67 | 290.91 | 0 | |
| Tangible book value per share | 0 | 186.59 | 0 | 195.01 | 0 | |
| Share holders equity per share | 262.2 | 273.96 | 275.67 | 290.91 | 0 | |
| Interest debt per share | 1.85 | 101.85 | 1.88 | 84.93 | 1.63 | |
| Market cap | 333.66B | 295.01B | 410.74B | 533.02B | 597.78B | |
| Enterprise value | 345.31B | 328.11B | 427.92B | 556.05B | 597.78B | |
| P/E ratio | 54.35 | 31.26 | 22.7 | 27.21 | 24.37 | |
| Price to sales ratio | 7.86 | 6.81 | 8.66 | 10.79 | 11.77 | |
| POCF ratio | 75.69 | 504.89 | 87.52 | 107.53 | 116.21 | |
| PFCF ratio | 75.69 | 504.89 | 87.52 | 107.53 | 116.21 | |
| P/B Ratio | 2.8 | 2.37 | 3.27 | 4.03 | 0 | |
| PTB ratio | 2.8 | 2.37 | 3.27 | 4.03 | 0 | |
| EV to sales | 8.14 | 7.58 | 9.02 | 11.26 | 11.77 | |
| Enterprise value over EBITDA | 62.71 | 53.35 | 48.68 | 58.03 | 56.01 | |
| EV to operating cash flow | 78.34 | 561.54 | 91.18 | 112.17 | 116.21 | |
| EV to free cash flow | 78.34 | 561.54 | 91.18 | 112.17 | 116.21 | |
| Earnings yield | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0.36 | 0 | 0.29 | 0 | |
| Debt to assets | 0 | 0.2 | 0 | 0.16 | 0 | |
| Net debt to EBITDA | 2.12 | 5.38 | 1.95 | 2.4 | 0 | |
| Current ratio | 0 | 1.34 | 0 | 1.41 | 0 | |
| Interest coverage | 3.93 | 3.79 | 7.26 | 8.81 | 10.95 | |
| Income quality | 2.87 | 0.25 | 1.04 | 1.01 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.07 | 0.05 | 0.08 | 0.08 | 0.07 | |
| Intangibles to total assets | 0 | 0.18 | 0 | 0.19 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Graham number | 141.1 | 178.79 | 248.3 | 265.38 | 0 | |
| ROIC | 0.02 | 0.02 | 0.04 | 0.03 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0.03 | 0 | |
| Graham Net | 25.61 | -54.7 | 37.75 | -47.46 | 0 | |
| Working capital | 11.65B | 31.86B | 17.18B | 36.67B | 0 | |
| Tangible asset value | 0 | 84.89B | 0 | 88.75B | 0 | |
| Net current asset value | 11.65B | 20.38B | 17.18B | 24.52B | 0 | |
| Invested capital | 0 | 0.36 | 0 | 0.29 | 0 | |
| Average receivables | 21.71B | 22.6B | 22.6B | 22.53B | 22.53B | |
| Average payables | 11.22B | 12.66B | 12.66B | 13.77B | 13.77B | |
| Average inventory | 23.4B | 22.46B | 22.46B | 23.37B | 23.37B | |
| Days sales outstanding | 0 | 93.93 | 0 | 82.09 | 0 | |
| Days payables outstanding | 0 | 130.19 | 0 | 145.6 | 0 | |
| Days of inventory on hand | 0 | 231 | 0 | 247.05 | 0 | |
| Receivables turnover | 0 | 0.96 | 0 | 1.1 | 0 | |
| Payables turnover | 0 | 0.69 | 0 | 0.62 | 0 | |
| Inventory turnover | 0 | 0.39 | 0 | 0.36 | 0 | |
| ROE | 0.01 | 0.02 | 0.04 | 0.04 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
LUPIN.NS Frequently Asked Questions
What is Lupin Limited stock symbol ?
Lupin Limited is a IN stock and trading under the symbol LUPIN.NS
What is Lupin Limited stock quote today ?
Lupin Limited stock price is $1594.05 today.
Is Lupin Limited stock public?
Yes, Lupin Limited is a publicly traded company.
Company Profile
- Volume Average 1.2M
- Market Capitalization 739.24B
- Employee 20.93K
- CEO Ms. Vinita D. Gupta
- Headquarters Mumbai,IN
- IPO Date 2001-09-10
-
Website
https://www.lupin.com 
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
